학술논문
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Document Type
Article
Author
Barco, Stefano; Voci, Davide; Held, Ulrike; Sebastian, Tim; Bingisser, Roland; Colucci, Giuseppe; Duerschmied, Daniel; Frenk, André; Gerber, Bernhard; Götschi, Andrea; Konstantinides, Stavros V; Mach, François; Robert-Ebadi, Helia; Rosemann, Thomas; Simon, Noemi R; Spechbach, Hervé; Spirk, David; Stortecky, Stefan; Vaisnora, Lukas; Righini, Marc; Kucher, Nils; Roth Zetzsche, Stéphanie; Spescha, Rebecca; Leeger, Claudia; Butscheid, Yulia; Probst, Eliane; Micieli, Evy; Forgo, Gabor; Johner, Fabian; Grigorean, Alexandru; Vatsakis, Georgios; Keller Lang, Dagmar; Rampini Speck, Silvana; Hasse, Barbara; Rueegg, Marco; Arnold, Isabelle; Nickel, Christian; Busch, Jeannette; Blondon, Marc; Glauser, Frédéric; Cittone, Micol G; Kessler, Chiara; Gjermeni, Diona; Olivier, Christoph B; Gauchel, Nadine; Biever, Paul; Hobohm, Lukas; Becker, Dorothea; Schindewolf, Marc; Kuenzi, Arnaud; Ulrich, Silvia
Source
In The Lancet Haematology August 2022 9(8):e585-e593
Subject
Language
ISSN
2352-3026